Indivior is a specialty pharmaceutical company focused on treating opioid use disorder (OUD). Its core product, SUBLOCADE, is a monthly long-acting injectable (LAI) buprenorphine formulation administered as a single subcutaneous injection, designed to suppress withdrawal symptoms, block opioid euphoria, and reduce cravings. SUBLOCADE generated $856M in net revenue in FY25, representing roughly 69% of total net revenue. Indivior also sells SUBOXONE Film, a daily buprenorphine/naloxone sublingual film that it no longer promotes following a 2020 DOJ settlement; the product faces significant generic competition but still contributes roughly 28% of net revenue. The U.S. accounts for roughly 85% of revenue. Key customer channels include organized health systems, criminal justice systems, independent clinicians, and payors — Indivior maintains coverage with roughly 90% of U.S. payors. SUBLOCADE is distributed exclusively through a restricted specialty pharmacy network under an FDA REMS program. Gross margins are in the low-to-mid 80% range, typical for branded specialty pharma; Indivior manufactures buprenorphine API at its own facility in the U.K. and outsources final SUBLOCADE formulation to a contract manufacturer. SUBLOCADE is protected by patents through 2031–2044 and faces no generic competition. Indivior's growth strategy centers on expanding overall LAI adoption in the OUD market, growing the commercial payor patient mix, and eventually acquiring commercial-stage assets in new therapeutic areas. Two Phase 2 pipeline assets — a quarterly LAI buprenorphine prodrug and a non-opioid OUD therapy — have data expected in Q2 2026.